These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32727149)

  • 1. Drug Repositioning of the α
    Florent R; Poulain L; N'Diaye M
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32727149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
    Yamada D; Nishimatsu H; Kumano S; Hirano Y; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Kume H; Homma Y
    Int J Urol; 2013 Dec; 20(12):1220-7. PubMed ID: 23600973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
    Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
    J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
    Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
    J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial comment from Dr Murtola to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
    Murtola TJ
    Int J Urol; 2013 Dec; 20(12):1227-8. PubMed ID: 23600459
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment from Dr Chen to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
    Chen IJ
    Int J Urol; 2013 Dec; 20(12):1227. PubMed ID: 23600404
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical evaluation of naftopidil enantiomers: Rat functional assays in vitro and estrogen/androgen induced rat benign prostatic hyperplasia model in vivo.
    Huang JJ; Cai Y; Yi YZ; Huang MY; Zhu L; He F; Liu XW; Huang BY; Yuan M
    Eur J Pharmacol; 2016 Nov; 791():473-481. PubMed ID: 27615445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
    Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.
    Hori Y; Ishii K; Kanda H; Iwamoto Y; Nishikawa K; Soga N; Kise H; Arima K; Sugimura Y
    Cancer Prev Res (Phila); 2011 Jan; 4(1):87-96. PubMed ID: 21205739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Masumori N; Hashimoto J; Itoh N; Tsukamoto T;
    Scand J Urol Nephrol; 2007; 41(5):422-9. PubMed ID: 17853040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Naftopidil on Plasma Monoamine Levels and Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
    Kadekawa K; Sugaya K; Mukoyama H; Sakumoto M; Shimabukuro H; Shimabukuro S; Matayoshi Y; Onaga T; Ashitomi K; Nishijima S
    Low Urin Tract Symptoms; 2016 May; 8(2):100-5. PubMed ID: 27111621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest.
    Kanda H; Ishii K; Ogura Y; Imamura T; Kanai M; Arima K; Sugimura Y
    Int J Cancer; 2008 Jan; 122(2):444-51. PubMed ID: 17918159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
    Maruyama O; Kawachi Y; Hanazawa K; Koizumi K; Yamashita R; Sugimura S; Honda S; Sugiyama Y; Saitoh T; Noto K
    Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib.
    Florent R; Weiswald LB; Lambert B; Brotin E; Abeilard E; Louis MH; Babin G; Poulain L; N'Diaye M
    Cell Death Dis; 2020 May; 11(5):380. PubMed ID: 32424251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients.
    Kojima Y; Sasaki S; Shinoura H; Hayase M; Kubota Y; Hayashi Y; Tsujimoto G; Kohri K
    Prostate; 2007 Sep; 67(12):1285-92. PubMed ID: 17626248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
    Kojima Y; Sasaki S; Oda N; Koshimizu TA; Hayashi Y; Kiniwa M; Tsujimoto G; Kohri K
    Prostate; 2009 Oct; 69(14):1521-8. PubMed ID: 19544328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review.
    Castiglione F; Benigni F; Briganti A; Salonia A; Villa L; Nini A; Di Trapani E; Capitanio U; Hedlund P; Montorsi F
    Curr Med Res Opin; 2014 Apr; 30(4):719-32. PubMed ID: 24188134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia.
    Funahashi Y; Hattori R; Matsukawa Y; Komatsu T; Sassa N; Gotoh M
    World J Urol; 2011 Apr; 29(2):225-31. PubMed ID: 20309563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells.
    Iwamoto Y; Ishii K; Kanda H; Kato M; Miki M; Kajiwara S; Arima K; Shiraishi T; Sugimura Y
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):933-939. PubMed ID: 28243746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.